Celerion’s VP of clinical research Phil Bach spoke with Outsourcing-pharma.com at DIA 2011, explaining that demand from several pharma industry customers was the key driver for its efforts to gain Brazilian approval.

Bach said that Brazil’s drug market is going to be worth around $11bn by 2015 and added that this, coupled with the country’s economic stability and improving healthcare infrastructure, Is attractive to pharma companies.

This content is copyright protected

However, if you would like to share the information in this article, you may use the headline, summary and link below: